|Articles|December 10, 2001
CDER News 12/5 and 12/6 2001
Author(s)BioPharm International Editors
New and generic drug approvals
Advertisement
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
New $82 Million Biopharma Launch Targets Rare Disease Development With AI-Driven Strategy
2
WHO Finalizes United States’ Withdrawal from Organization: Report
3
GSK’s Arexvy Gains EU Approval for Adults Aged 18 Years and Older
4
Green Chemistry’s Role in Advancing US Chemical Innovation
5